Remove 2017 Remove Immunization Remove Labelling
article thumbnail

Janssen files its first CAR-T therapy cilta-cel in Europe

pharmaphorum

BMS and bluebird had been hoping for a label allowing third-line use. Janssen entered into a worldwide collaboration and license agreement for cilta-cel with the drug’s originator – China’s Legend Biotech – in December 2017.

article thumbnail

ASCO21: Gilead sets up first FDA okay for adult ALL with Tecartus data

pharmaphorum

Kymriah (tisagenlecleucel) was approved for relapsed/refractory ALL in 2017, but its label covers use in children and young adults aged up to 25, who account for the bulk of cases of the blood cancer. Around a quarter of patients treated with Tecartus had a severe immune reaction, and there were two deaths in the trial.

Labelling 105
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Positive safety data for long-term use of MS drug Kesimpta

pharmaphorum

The findings were based on an ALITHIOS Phase 3b open-label extension study of Kesimpta, a targeted B-cell therapy that Novartis says, “delivers superior efficacy with a similar safety and tolerability profile compared with teriflunomide, a first-line treatment for MS.”. years vs initiation two years later. billion in 2019.

article thumbnail

The Best Probiotics for Hashimoto’s

The Thyroid Pharmacist

This irritation can interrupt the immune system’s ability to regulate itself, and put the body into a perpetual “attack mode” that is counterproductive to healing. Immune system health and gut health are linked. They can help improve digestion and nutrient extraction from the foods we eat, and can also balance the immune system.

article thumbnail

Almirall/Lilly lebrikizumab offers potential long-term management of atopic dermatitis

pharmaphorum

As Dr Thyssen further explained, “[i]t all started with the approval of the first biologic in 2017, and has been followed by the approval of other drugs, including one biologic and [three] oral drugs, in the past [one to two] years.

article thumbnail

Targeting tumours with novel radiopharmaceuticals

European Pharmaceutical Review

Granzyme B is an enzyme released by activated immune cells and using this as a in vivo imaging biomarker has great potential to monitor immune cell activation in a variety of inflammatory diseases, autoimmune diseases, cancer and infections. References Meeting rising demands of a new radiotheranostic era. Internet] Jaafar-Thiel, L.

article thumbnail

Are Flame Retardant Toxins Contributing to Your Thyroid Condition?

The Thyroid Pharmacist

Several years ago, after reading research about all of the toxins commonly used in flame retardants (and learning about all of the many products in my home that contain these chemicals… somewhat of a shocking list), I looked at my mattress label, only to learn it contained one of the chief offenders. Labels (Furniture, Fabrics, and Carpet).